Sanofi shares jump on solid Q1 ahead of new CEO arrival

(Sharecast News) - Shares in Sanofi rose as the French pharma giant beat first-quarter sales estimates on Thursday on continuing demand for its Dupixent asthma and eczema drug just before the arrival of new chief executive Belén Garijo. Dupixent sales increased by 30.8% to €4.2 billion. The company reported total sales of €10.51bn for the three months to March 31, up 6.2%. Analysts on average expected sales of €10.22bn. Shares in the company were up 3.3% in Paris.

Quarterly business operating income rose 2.2% to €2.97bn, beating estimates of €2.85bn.

"We reiterate our guidance for 2026: we continue to expect sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, at constant exchange rates, delivering profitable growth. We are also looking forward to welcoming Belén Garijo as the new CEO of Sanofi from next month," said interim boss Olivier Charmeil.

Reporting by Frank Prenesti for Sharecast.com